Jazz Pharmaceuticals plc JAZZ

NAS: JAZZ | ISIN: IE00B4Q5ZN47   11/10/2024
108,80 USD (+0,86%)
(+0,86%)   11/10/2024
Grafiek Jazz Pharmaceuticals plc Grafiek Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc in het nieuws

9 september 2024 · Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024 · Persbericht

5 september 2024 · Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024 · Persbericht

4 september 2024 · Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases · Persbericht

3 september 2024 · Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases · Persbericht

22 augustus 2024 · Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies · Persbericht

21 augustus 2024 · Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences · Persbericht

31 juli 2024 · Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance · Persbericht

25 juli 2024 · Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting · Persbericht

22 juli 2024 · Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026 · Persbericht

17 juli 2024 · Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024 · Persbericht

Profiel Jazz Pharmaceuticals plc

Fabricage van farmaceutische preparaten
Farmaceutische producten: Andere
Gezondheidstechnologie
Productie

CEO: Bruce Cozadd

Werknemers: 3.199

Aandelen Jazz Pharmaceuticals plc

Beurswaarde: 7,19 miljard USD

Effecten: 61,75 miljoen

Winst per aandeel (12 maand):  PLUS

Koers-winstverhouding:  PLUS

Beta: 0,46

Mijn selecties